大学ホーム医学研究科教育・研究指導教員紹介:福原 浩

教員紹介:福原 浩


氏名
 
福原 浩
フクハラ ヒロシ FUKUHARA, Hiroshi
職位 教授
学内の役職・委員等 教授
所属教室
専攻・専門分野
 (大学院)
担当科目(学部) 泌尿器科学
担当科目(大学院) 泌尿器科学演習、泌尿器腫瘍学
専門分野 泌尿器腫瘍学、腹腔鏡・ロボット手術、ウイルス療法
研究テーマ 1.がん治療用ウイルスを用いたウイルス療法
2.泌尿器癌におけるがんゲノム医療
3.泌尿器癌におけるメタボローム解析
略歴 1995年 東京大学医学部医学科卒業
2001年 米国ハーバード大学(MGH病院) フェロー
2006年 東京大学医学部泌尿器科 講師
2014年 東京大学大学院医学系研究科泌尿器外科 准教授
2018年 杏林大学医学部泌尿器科 教授
所有する学位 博士(医学)
指導医・専門医・認定医、その他の資格等 日本泌尿器科学会:専門医・指導医、泌尿器腹腔鏡技術認定医、日本内視鏡外科学会技術認定医、癌治療認定医・暫定教育医、腹腔鏡下小切開手術施設基準医認定医、泌尿器ロボット支援手術プロクター認定医
論文・著書等を含む主要研究業績 1 欧文原著
1. Watanabe S, Hayashi K, Toh K, Kim HJ, Liu X, Chaya H, Fukushima S, Katsushima K, Kondo Y, Uchida S, Ogura S, Nomoto T, Takemoto H, Cabral H, Kinoh H, Tanaka HY, Kano MR, Matsumoto Y, Fukuhara H, Uchida S, Nangaku M, Osada K, Nishiyama N, Miyata K, Kataoka K. In vivo rendezvous of small nucleic acid drugs with charge-matched block catiomers to target cancers. Nat Commun. 10, 1894, 2019.
2. Fujimura T, Igawa Y, Aizawa N, Niimi A, Yamada Y, Sugihara T, Kamei J, Sato Y, Matsunaga A, Yoshida M, Shinoda Y, Fukuhara H, Nakagawa T, Homma Y, Kume H. Longitudinal change of comprehensive lower urinary tract symptoms and various types of urinary incontinence during robot-assisted radical prostatectomy. Neurourol Urodyn 38, 1067-1075, 2019.
3. Akiyama Y, Daichi M, Katoh H, Morikawa T, Niimi A, Nomiya A, Sato Y, Kawai T, Goto A, Fujimura T, Fukuhara H, Nakagawa T, Igawa Y, Ishikawa S, Fukayama M, Kume H, Homma Y. Molecular Taxonomy of Interstitial Cystitis/Bladder Pain Syndrome Based on Whole Transcriptome Profiling by Next-Generation RNA Sequencing of Bladder Mucosal Biopsies. J Urol. 2019, in press.
4. Kinjo M, Yamaguchi T, Tambo M, Okegawa T, Fukuhara H. Effects of Mirabegron on Anxiety and Depression in Female Patients with Overactive Bladder. Urol Int. 2019, in press.
5. Fujimura T, Fukuhara H, Yamada Y, Taguchi S, Sugihara T, Niimi A, Nakamura M, Nakagawa T, Igawa Y, Homma Y, Kume H. Aggressive Cancer Behavior of Latent Gleason Pattern 5 in Prostatectomy Specimens. Anticancer Res. 38: 6529-6535, 2018.
6. Kinoshita Y, Sugihara T, Yasunaga H, Matsui H, Ishikawa A, Fujimura T, Fukuhara H, Ishibashi Y, Fushimi K, Homma Y. Hospital-volume effects on perioperative outcomes in peritoneal dialysis catheter implantation: analysis of 2,505 cases. Perit Dial Int. 38, 419-423, 2018.
7. Taguchi S, Fukuhara H*, Miyakawa J, Morikawa T, Naito A, Kawai T, Fujimura T, Kume H. Prognostic significance of neutrophil-to-lymphocyte ratio in collecting duct carcinoma. Jpn J Clin Oncol. 48, 692-694, 2018.
8. Otsuka M, Taguchi S, Nakagawa T, Morikawa T, Maekawa S, Miyakawa J, Matsumoto A, Miyazaki H, Fujimura T, Fukuhara H, Kume H, Igawa Y, Homma Y. Clinical significance of random bladder biopsy in primary T1 bladder cancer. Mol Clin Oncol. 8, 665-670, 2018.
9. Makino K, Nakagawa T, Ito E, Kasahara I, Murata T, Fujimura T, Fukuhara H, Homma Y. Oncological and peri-surgical outcomes of radical prostatectomy for non-metastatic prostate cancer with prostate-specific antigen level of 50 ng/ml or greater. Jpn J Clin Oncol. 48, 485-49, 2018.
10. Aizawa N, Watanabe D, Fukuhara H, Fujimura T, Kume H, Homma Y, Igawa Y. Inhibitory effects of silodosin on the bladder mechanosensitive afferent activities and their relation with bladder myogenic contractions in male rats with bladder outlet obstruction. Neurourol Urodyn. 37, 1897-1903, 2018.
11. Akiyama Y, Niimi A, Nomiya A, Yamada Y, Nakagawa T, Fujimura T, Fukuhara H, Kume H, Igawa Y and Homma Y. Extent of Hunner lesions: the relationships with symptom severity and clinical parameters in patients with Hunner-type interstitial cystitis. Neurourol Urodyn. 37, 1441-1447, 2018.
12. Niimi A, Igawa Y, Aizawa N, Honma T, Nomiya A, Akiyama Y, Kamei J, Fujimura T, Fukuhara H and Homma Y. Diagnostic value of urinary CXCL10 as a biomarker for predicting Hunner type interstitial cystitis. Neurourol Urodyn. 37, 1113-1119, 2018.
13. Yamada Y, Fujimura T, Fukuhara H, Sugihara T, Nakagawa T, Kume H, Igawa Y, Homma Y. Predictors of Early Continence after Robot-assisted Radical Prostatectomy. Low Urin Tract Symptoms. 10, 287-291, 2018.
14. Matsumoto A, Nakagawa T, Kanatani A, Ikeda M, Kawai T, Miyakawa J, Taguchi S, Naito A, Otsuka M, Nakanishi Y, Suzuki M, Koga F, Nagase Y, Kondo Y, Okaneya T, Tanaka Y, Miyazaki H, Fujimura T, Fukuhara H, Kume H, Igawa Y, Homma Y. Preoperative chronic kidney disease is predictive of oncological outcome of radical cystectomy for bladder cancer. World J Urol. 36, 249-256, 2018.
15. Miyakawa J, Taguchi S, Suzuki M, Endo K, Nose Y, Sato T, Ishikawa A, Fukuhara H, Homma Y. Impact of monthly 120 mg denosumab on bone metabolism in bone-metastatic prostate cancer undergoing androgen deprivation therapy. Asian Pacific Journal of Cancer Care 2, 55-60, 2017.
16. Aizawa N, Ichihara K, Fukuhara H, Fujimura T, Andersson KE, Homma Y, Igawa Y. Characteristics of the mechanosensitive bladder afferent activities in relation with microcontractions in male rats with bladder outlet obstruction. Sci Rep. 7, 7646, 2017.
17. Yamada Y, Fujimura T, Fukuhara H, Sugihara T, Miyazaki H, Nakagawa T, Kume H, Igawa Y, Homma Y. Overactive bladder is a negative predictor of achieving continence after robot-assisted radical prostatectomy. Int J Urol. 24, 749-756, 2017.
18. Nakagawa T, Taguchi S, Kanatani A, Kawai T, Ikeda M, Urakami S, Matsumoto A, Komemushi Y, Miyakawa J, Yamada D, Suzuki M, Enomoto Y, Nishimatsu H, Kondo Y, Nagase Y, Hirano Y, Okaneya T, Tanaka Y, Miyazaki H, Fujimura T, Fukuhara H, Kume H, Igawa Y, Homma Y. Oncological Outcome of Metastasectomy for Urothelial Carcinoma: Who is the Best Candidate? Annals of Surgical Oncology 24, 2794-2800, 2017.
19. Fujimura T, Fukuhara H, Taguchi S, Yamada Y, Sugihara T, Nakagawa T, Niimi A, Kume H, Igawa Y, Homma Y. Robot-assisted radical prostatectomy significantly reduced biochemical recurrence compared to retro pubic radical prostatectomy. BMC Cancer 17, 454, 2017.
20. Sugihara T, Yasunaga H, Matsui H, Nagao G, Ishikawa A, Fujimura T, Fukuhara H, Fushimi K, Ohori M, Homma Y. Accessibility to surgical robot technology and prostate-cancer patient behavior for prostatectomy. Jpn J Clin Oncol. 47, 647-651, 2017.
21. Nakagawa T, Komemushi Y, Kawai T, Otsuka M, Miyakawa J, Uemura Y, Kanatani A, Taguchi S, Naito A, Suzuki M, Nishimatsu H, Hirano Y, Tanaka Y, Matsumoto A, Miyazaki H, Fujimura T, Fukuhara H, Kume H, Igawa Y, Homma Y. Efficacy of post-nephroureterectomy cisplatin-based adjuvant chemotherapy for locally advanced upper tract urothelial carcinoma: a multi-institutional retrospective study. World J Urol. 35, 1569-1575, 2017.
22. Sugiyama R, Aizawa N, Ito H, Fujimura T, Suzuki M, Nakagawa T, Fukuhara H, Kume H, Homma Y, Igawa Y. Synergic Suppressive Effect of Silodosin and Imidafenacin on Non-Voiding Bladder Contractions in Male Rats with Subacute Bladder Outlet Obstruction. Low Urin Tract Symptoms. 9, 94-101, 2017.
23. Yamada Y, Fujimura T, Fukuhara H, Sugihara T, Takemura K, Kakutani S, Suzuki M, Nakagawa T, Kume H, Igawa Y, Homma Y. Incidence and risk factors of inguinal hernia after robot-assisted radical prostatectomy. World J Surg Oncol. 15, 61, 2017.
24. Taguchi S, Buti S, Fukuhara H*, Otsuka M, Bersanelli M, Morikawa T, Miyazaki H, Nakagawa T, Fujimura T, Kume H, Igawa Y, Homma Y. Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality? PLoS One 12: e0172341, 2017.
25. Kamei J, Yagihara Y, Kume H, Horiuchi T, Sato T, Nakagawa T, Fujimura T, Fukuhara H, Moriya K, Homma Y. Prevalence and characteristics of fecal antimicrobial-resistant Escherichia coli in a cohort of Japanese men undergoing prostate biopsy. Int J Urol. 24, 295-300, 2017.
26. Aizawa N, Ito H, Sugiyama R, Fujimura T, Fukuhara H, Kume H, Homma Y, Igawa Y. Effects of Sildenafil, a Phosphodiesterase Type 5 Inhibitor, on the Primary Single Afferent Activity of the Rat Bladder. Low Urin Tract Symptoms. 9, 57-61, 2017.
27. Nakagawa T, Taguchi S, Uemura Y, Kanatani A, Ikeda M, Matsumoto A, Yoshida K, Kawai T, Nagata M, Yamada D, Komemushi Y, Suzuki M, Enomoto Y, Nishimatsu H, Ishikawa A, Nagase Y, Kondo Y, Tanaka Y, Okaneya T, Hirano Y, Shinohara M, Miyazaki H, Fujimura T, Fukuhara H, Kume H, Igawa Y, Homma Y. Nomogram for predicting survival of postcystectomy recurrent urothelial carcinoma of the bladder. Urol Oncol. 35, 457.e15-457.e21, 2017.
28. Naito A, Taguchi S, Nakagawa T, Matsumoto A, Nagase Y, Tabata M, Miyakawa J, Suzuki M, Nishimatsu H, Enomoto Y, Takahashi S, Okaneya T, Yamada D, Tachikawa T, Minowada S, Fujimura T, Fukuhara H, Kume H, Homma Y. Prognostic significance of serum neuron-specific enolase in small cell carcinoma of the urinary bladder. World J Urol. 35, 97-103, 2017.
29. Makino K, Nakagawa T, Kanatani A, Kawai T, Taguchi S, Otsuka M, Matsumoto A, Miyazaki H, Fujimura T, Fukuhara H, Kume H, Homma Y. Biphasic decline in renal function after radical cystectomy with urinary diversion. Int J Clin Oncol. 22, 359-365, 2017.
30. Yamada Y, Nakagawa T, Sugihara T, Horiuchi T, Yoshizaki U, Fujimura T, Fukuhara H, Urano T, Takayama K, Inoue S, Kume H, Homma Y. Prognostic value of CD66b positive tumor-infiltrating neutrophils in testicular germ cell tumor. BMC Cancer 16: 898, 2016.
31. Nozaki K, Kamijo Y, Nakatsuka M, Azuma T, Nakagawa T, Miyazaki H, Fujimura T, Fukuhara H, Kume H, Ishibashi Y, Homma Y. Computed tomography for the management of exit-site and tunnel infections in peritoneal dialysis patients. Clin Nephrol. 86, 328-332, 2016.
32. Aizawa N, Fukuhara H, Fujimura T, Homma Y, Igawa Y. Direct influence of systemic desensitization by resiniferatoxin on the activities of Aδ- and C-fibers in the rat primary bladder mechanosensitive afferent nerves. Int J Urol. 23, 952-56, 2016.
33. Yamada Y, Takayama KI, Fujimura T, Ashikari D, Obinata D, Takahashi S, Ikeda K, Kakutani S, Urano T, Fukuhara H, Homma Y, Inoue S. A novel prognostic factor TRIM44 promotes cell proliferation and migration and inhibits apoptosis in testicular germ cell tumor. Cancer Sci. 108, 32-41, 2016.
34. Ito H, Kamei J, Aizawa N, Fujita Y, Suzuki M, Fukuhara H, Fujimura T, Kojima T, Homma Y, Kubota Y, Ito M, Andersson KE, Igawa Y. Preventive effects of long-term caloric restriction on aging-related in vivo bladder dysfunctions and molecular biological changes in the bladder and dorsal root ganglia in rat. J Urol. 196, 1575-1583, 2016.
35. Taguchi S, Fukuhara H*, Morikawa T, Matsumoto A, Miyazaki H, Nakagawa T, Fujimura T, Kume H, Igawa Y, Homma Y. Cessation of long-term adjuvant androgen deprivation therapy after radical prostatectomy: is it feasible? Jpn J Clin Oncol. 46, 1143-1147, 2016.
36. Taguchi S, Shiraishi K, Fukuhara H*, Nakagawa K, Morikawa T, Naito A, Kakutani S, Takeshima Y, Miyazaki H, Nakagawa T, Fujimura T, Kume H, Homma Y. Optimal timing of salvage radiotherapy for biochemical recurrence after radical prostatectomy: is ultra-early salvage radiotherapy beneficial? Radiat Oncol. 11, 102-107, 2016.
37. Niimi A, Suzuki M, Yamaguchi Y, Ishii M, Fujimura T, Nakagawa T, Fukuhara H, Kume H, Igawa Y, Akishita M, Homma Y. Sleep apnea and circadian extracellular fluid change as an independent factor for nocturnal polyuria. J Urol. 196, 1183-1189, 2016.
38. Taguchi S, Shiraishi K, Fukuhara H*, Nakagawa K, Morikawa T, Naito A, Kakutani S, Takeshima Y, Miyazaki H, Nakagawa T, Fujimura T, Kume H, Homma Y. Impact of Gleason pattern 5 including tertiary pattern 5 on outcomes of salvage treatment for biochemical recurrence in pT2-3N0M0 prostate cancer. Int J Clin Oocol. 21, 975-980, 2016.
39. Taguchi S, Kume H, Fukuhara H*, Morikawa T, Kakutani S, Takeshima Y, Miyazaki H, Suzuki M, Fujimura T, Nakagawa T, Ishikawa A, Igawa Y, Homma Y. Symptoms at diagnosis as independent prognostic factors in retroperitoneal liposarcoma. Mol Clin Oncol. 4, 255-260, 2016.
40. Yamada Y, Fujimura T, Fukuhara H, Miyagawa J, Miyazaki H, Nakagawa T, Kume H, Homma Y. Measuring Contact Pressure of Lower Extremities in Patients Undergoing Robot-Assisted Radical Prostatectomy. Urol Int. 96, 268-273, 2016.
41. Fujimura T, Menon M, Fukuhara H, Kume H, Suzuki M, Yamada Y, Niimi A, Nakagawa T, Igawa Y, Homma Y. Validation of an educational program balancing surgeon training and surgical quality control during robot-assisted radical prostatectomy. Int J Urol. 23, 160-166, 2016.
42. Otsuka M, Taguchi S, Nakagawa T, Kawai T, Morikawa T, Miyazaki H, Fujimura T, Fukuhara H, Kume H, Homma Y. Lower ureteral lesion is an independent predictor of intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinoma. Urol Oncol. 34, 59e9-13, 2016.
43. Taguchi S, Akamatsu N, Nakagawa T, Gonoi W, Kanatani A, Miyazaki H, Fujimura T, Fukuhara H, Kume H, Homma Y. Sarcopenia Evaluated Using the Skeletal Muscle Index Is a Significant Prognostic Factor for Metastatic Urothelial Carcinoma. Clin Genitourin Cancer. 14, 237-243, 2016.
44. Aizawa N, Sugiyama R, Ichihara K, Fujimura T, Fukuhara H, Homma Y, Igawa Y. Functional roles of the bladder alpha1-adrenoceptors in the activation of single-unit primary bladder afferent activity in rats. BJU Int. 117, 993-1001, 2016.
45. Niimi A, Nomiya A, Yamada Y, Suzuki M, Fujimura T, Fukuhara H, Kume H, Igawa Y, Homma Y. Hydrodistension with or without fulguration of hunner lesions for interstitial cystitis: Long-term outcomes and prognostic predictors. Neurourol Urodyn. 35, 965-969, 2016.
46. Ito H, Aizawa N, Sugiyama R, Watanabe S, Takahashi N, Tajimi M, Fukuhara H, Homma Y, Kubota Y, Andersson KE, Igawa Y. Functional role of the TRPM8 ion channel in the urinary bladder assessed by conscious cystometry and ex vivo measurements of single-unit mechanosensitive bladder afferent activities in the rat. BJU Int. 117, 484-494, 2016.
47. Aizawa N, Gandaglia G, Hedlund P, Fujimura T, Fukuhara H, Montorsi F, Homma Y, Igawa Y. URB937, a peripherally-restricted inhibitor for fatty acid amide hydrolase, reduces prostaglandin E2 -induced bladder overactivity and hyperactivity of bladder mechano-afferent nerve fibers in rats. BJU Int. 117, 821-828, 2016.
48. Fujimura T, Takahashi S, Kume H, Urano T, Takayama K, Yamada Y, Suzuki M, Fukuhara H, Nakagawa T, Inoue S, Homma Y. Toremifene, a selective estrogen receptor modulator, significantly improved biochemical recurrence in bone metastatic prostate cancer: a randomized controlled phase II a trial. BMC Cancer. 15, 836, 2015.
49. Taguchi S, Fukuhara H*, Shiraishi K, Nakagawa K, Morikawa T, Kakutani S, Takeshima Y, Miyazaki H, Fujimura T, Nakagawa T, Kume H, Homma Y. Radical Prostatectomy versus External Beam Radiotherapy for cT1-4N0M0 Prostate Cancer: Comparison of Patient Outcomes Including Mortality. PLoS One. 10, e0141123, 2015.
50. Kamei J, Furuta A, Akiyama Y, Niimi A, Ichihara K, Fujimura T, Fukuhara H, Kume H, Homma Y, Igawa Y. Video-urodynamic effects of mirabegron, a β3 -adrenoceptor agonist, in patients with low-compliance bladder. Int J Urol. 22, 956-961, 2015.
51. Taguchi S, Nakagawa T, Uemura Y, Matsumoto A, Nagase Y, Kawai T, Tanaka Y, Yoshida K, Yamamoto S, Enomoto Y, Nose Y, Sato T, Ishikawa A, Fujimura T, Fukuhara H, Kume H, Homma Y. Validation of major prognostic models for metastatic urothelial carcinoma using a multi-institutional cohort of the real world. World J Urol. 34, 163-171, 2016.
52. Akiyama Y, Nomiya A, Niimi A, Yamada Y, Fujimura T, Nakagawa T, Fukuhara H, Kume H, Igawa Y, Homma Y. Botulinum toxin type A injection for refractory interstitial cystitis: A randomized comparative study and predictors of treatment response. Int J Urol. 22, 835-41, 2015.
53. Taguchi S, Nakagawa T, Matsumoto A, Nagase Y, Kawai T, Tanaka Y, Yoshida K, Yamamoto S, Enomoto Y, Nose Y, Sato T, Ishikawa A, Uemura Y, Fujimura T, Fukuhara H, Kume H, Homma Y. Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of survival in patients with metastatic urothelial carcinoma: A multi-institutional study. Int J Urol. 22, 638-43, 2015.
54. Nishimatsu H, Suzuki E, Saito Y, Niimi A, Nomiya A, Fukuhara H, Kume H, Homma Y. Senescent Cells Impair Erectile Function through Induction of Endothelial Dysfunction and Nerve Injury in Mice. PLoS One. 10, e0124129, 2015.
55. Kume H, Kawai T, Nagata M, Azuma T, Miyazaki H, Suzuki M, Fujimura T, Nakagawa T, Fukuhara H, Homma Y. Intermittent docetaxel chemotherapy is feasible for castration-resistant prostate cancer. Molecular and Clinical Oncology. 3, 303-307, 2015.
56. Fujimura T, Yamada Y, Sugihara T, Azuma T, Suzuki M, Fukuhara H, Nakagawa T, Kume H, Igawa Y, Homma Y. Nocturia in men is a chaotic condition dominated by nocturnal polyuria. Int J Urol. 22, 496-501, 2015.
57. Kanatani A, Nakagawa T, Kawai T, Naito A, Sato Y, Yoshida K, Nozaki K, Nagata M, Yamada Y, Azuma T, Suzuki M, Fujimura T, Fukuhara H, Nishimatsu H, Kume H, Igawa Y, Homma Y. Adjuvant Chemotherapy Is Possibly Beneficial for Locally Advanced or Node-Positive Bladder Cancer. Clin Genitourin Cancer. 13, e107-112, 2015.
58. Ito H, Aizawa N, Fujita Y, Suzuki M, Fukuhara H, Homma Y, Kubota Y, Ito M, Andersson KE, Igawa Y. Long-term caloric restriction in rats may prevent age-related impairment of in vitro bladder function. J Urol. 193, 2123-30, 2015.
59. Kakutani S, Fukuhara H, Taguchi S, Nagata M, Niimi A, Hattori M, Miyazaki H, Fujimura T, Nakagawa T, Kume H, Igawa Y, Homma Y. Combination of docetaxel, ifosfamide and cisplatin (DIP) as a potential salvage chemotherapy for metastatic urothelial carcinoma. Jpn J Clin Oncol. 45, 281-5, 2015.
60. Aizawa N, Ito H, Sugiyama R, Fujimura T, Suzuki M, Fukuhara H, Homma Y, Igawa Y. Selective inhibitory effect of imidafenacin and 5-hydroxymethyl tolterodine on capsaicin-sensitive C-fibers of the primary bladder mechanosensitive afferent nerves in the rat. J Urol. 193, 1423-32, 2015.
61. Matsushita H, Enomoto Y, Kume H, Nakagawa T, Fukuhara H, Suzuki M, Fujimura T, Homma Y, Kakimi K. A pilot study of autologous tumor lysate-loaded dendritic cell vaccination combined with sunitinib for metastatic renal cell carcinoma. J Immunother Cancer. 2, 30, 2014.
62. Yamada D, Matsushita H, Azuma T, Nakagawa T, Nagata M, Yamada Y, Suzuki M, Fujimura T, Fukuhara H, Kume H, Homma Y, Kakimi K. Granulocyte macrophage colony-stimulating factor as a predictor of the response of metastatic renal cell carcinoma to tyrosine kinase inhibitor therapy. Mol Clin Oncol. 2, 1023-1027, 2014.
63. Taguchi S, Fukuhara H*, Kakutani S, Takeshima Y, Miyazaki H, Suzuki M, Fujimura T, Nakagawa T, Igawa Y, Kume H, Homma Y. Risk factors for clinical metastasis in men undergoing radical prostatectomy and immediate adjuvant androgen deprivation therapy. Asian Pac J Cancer Prev. 15, 10729-33, 2014.
64. Taguchi S, Fukuhara H*, Azuma T, Suzuki M, Fujimura T, Nakagawa T, Ishikawa A, Kume H, Igawa Y, Homma Y. Ultra-early versus early salvage androgen deprivation therapy for post-prostatectomy biochemical recurrence in pT2-4N0M0 prostate cancer. BMC Urol. 14, 81-86, 2014.
65. Sugihara T, Yasunaga H, Horiguchi H, Matsui H, Fujimura T, Nishimatsu H, Fukuhara H, Kume H, Yu C, Kattan MW, Kiyohide F, Homma Y. Robot-assisted versus other types of radical prostatectomy: population-based safety and cost comparison in Japan, 2012-2013. Cancer Sci. 105, 1421-1426, 2014.
66. Nishimatsu H, Kitamura Y, Yamada D, Nomiya A, Niimi A, Suzuki M, Fujimura T, Fukuhara H, Nakagawa T, Enomoto Y, Kume H, Igawa Y, Homma Y. Improvement of symptoms of aging in males by a preparation LEOPIN ROYAL containing aged garlic extract and other five of natural medicines - comparison with traditional herbal medicines (Kampo). Aging Male. 17, 112-116, 2014.
67. Sato YT, Fukuhara H*, Suzuki M, Fujimura T, Nakagawa T, Nishimatsu H, Kume H, Morikawa T, Fukayama M, Homma Y. Long-term results of radical prostatectomy with immediate adjuvant androgen deprivation therapy for pT3N0 prostate cancer. BMC Urol. 14, 13-18, 2014.
68. Kamei J, Nishimatsu H, Nakagawa T, Suzuki M, Fujimura T, Fukuhara H, Igawa Y, Kume H, Homma Y. Risk factors for septic shock in acute obstructive pyelonephritis requiring emergency drainage of the upper urinary tract. Int Urol Nephrol. 46, 493-497; 2014.
69. Taguchi S, Nakagawa T, Hattori M, Niimi A, Nagata M, Kawai T, Fukuhara H, Nishimatsu H, Ishikawa A, Kume H, Homma Y. Prognostic Factors for Metastatic Urothelial Carcinoma Undergoing Cisplatin-based Salvage Chemotherapy. Jpn J Clin Oncol. 43, 923-928, 2013.
70. Nishimatsu H, Suzuki E, Nomiya A, Niimi A, Suzuki M, Fujimura T, Fukuhara H, Homma Y. Adrenomedullin and Angiopoietin-1 Additively Restore Erectile Function in Diabetic Rats: Comparison with the Combination Therapy of Vascular Endothelial Growth Factor and Angiopoietin-1. J Sex Med. 10, 1707-1709, 2013.
71. Yamada D, Nishimatsu H, Kumano S, Hirano Y, Suzuki M, Fujimura T, Fukuhara H, Enomoto Y, Kume H, Homma Y. Reduction of prostate cancer incidence by naftopidil, an α1 -adrenoceptor antagonist and transforming growth factor-β signaling inhibitor. Int J Urol. 20, 1220-1227, 2013.
72. Miyazaki H, Kume H, Suzuki M, Fujimura T, Fukuhara H, Enomoto Y, Nishimatsu H, Homma Y. Leukopenia as a risk factor for osteonecrosis of the jaw in metastatic prostate cancer receiving zoledronic acid and docetaxel. BJU Int. 110, E520-525, 2012.
73. Nakamura M, Fujimura T, Nagata M, Hosoda C, Suzuki M, Fukuhara H, Enomoto Y, Nishimatsu H, Kume H, Igawa Y, Homma Y. Association between lower urinary tract symptoms and sexual dysfunction assessed using the core lower urinary tract symptom score and International index of erectile function-5 questionnaires. Aging Male. 15, 111-114, 2012.
74. Sugihara T, Yasunaga H, Horiguchi H, Nishimatsu H, Fukuhara H, Enomoto Y, Kume H, Ohe K, Matsuda S, Homma Y. Management trends, angioembolization performance and multiorgan injury indicators of renal trauma from Japanese administrative claims database. Int J Urol. 19, 559-563, 2012.
75. Fujimura T, Kume H, Nishimatsu H, Sugihara T, Nomiya A, Tsurumaki Y, Miyazaki H, Suzuki M, Fukuhara H, Enomoto Y, Homma Y. Assessment of lower urinary tract symptoms in men by international prostate symptom score and core lower urinary tract symptom score. BJU Int. 109, 1512-1516, 2012.
76. Nagata M, Sakurai-Yageta M, Yamada D, Goto A, Ito A, Fukuhara H, Kume H, Morikawa T, Fukayama M, Homma Y, Murakami Y. Aberrations of a cell adhesion molecule CADM4 in renal clear cell carcinoma. Int J Cancer 130, 1329-1337, 2012.
77. Tanikawa M, Wada-Hiraike O, Nakagawa S, Shirane A, Hiraike H, Koyama S, Miyamoto Y, Sone K, Tsuruga T, Nagasaka K, Matsumoto Y, Ikeda Y, Shoji K, Oda K, Fukuhara H, Nakagawa K, Kato S, Yano T, Taketani Y. Multifunctional transcription factor TFII-I is an activator of BRCA1 function. Br J Cancer. 10, 1349-55, 2011.
78. Suzuki M, Fujimura T, Fukuhara H, Enomoto Y, Nishimatsu H, Ishikawa A, Kume H, Homma Y, Kitamura T. 17β-Estradiol-Mediated Elevation of Peripheral White Blood Cell Count During Estramustine Phosphate Therapy for Prostate Cancer. Int J Endocrinol Metab. 9, 347-351, 2011
79. Fujimura T, Kume H, Tsurumaki Y, Yoshimura Y, Hosoda C, Suzuki M, Fukuhara H, Enomoto Y, Nishimatsu H, Homma Y. Core lower urinary tract symptom score (CLSS) for the assessment of female lower urinary tract symptoms: a comparative study. Int J Urol. 18, 778-84, 2011.
80. Suzuki M, Liu M, Kurosaki T, Suzuki M, Arai T, Sawabe M, Kasuya Y, Kato M, Fujimura T, Fukuhara H, Enomoto Y, Nishimatsu H, Ishikawa A, Kume H, Homma Y, Kitamura T. Association of rs6983561 Polymorphism at 8q24 With Prostate Cancer Mortality in a Japanese Population. Clin Genitourin Cancer. 9, 46-52, 2011.
81. Kume H, Suzuki M, Fujimura T, Fukuhara H, Enomoto Y, Nishimatsu H, Ishikawa A, Homma Y. Docetaxel as a vital option for corticosteroid-refractory prostate cancer. Int Urol Nephrol. 185, 1611-1614, 2011.
82. Kume H, Kakutani S, Yamada Y, Shinohara M, Tominaga T, Suzuki M, Fujimura T, Fukuhara H, Enomoto Y, Nishimatsu H, Homma Y. Prognostic Factors for Renal Cell Carcinoma With Bone Metastasis: Who Are the Long-Term Survivors? J Urol. 185, 1611-1614, 2011.
83. Fukuhara H*, Nishimatsu H, Suzuki M, Fujimura T, Enomoto Y, Ishikawa A, Kume H, Homma Y. Lower incidence of inguinal hernia after radical prostatectomy using open gasless endoscopic single-site surgery. Prostate Cancer Prostatic Dis. 14, 162-167, 2011.
84. Fukuhara H*, Kume H, Suzuki M, Fujimura T, Enomoto Y, Nishimatsu H, Ishikawa A, Homma Y. Maximum tumor diameter: a simple independent predictor for biochemical recurrence after radical prostatectomy. Prostate Cancer Prostatic Dis. 13, 244-247, 2010.
85. Kume H, Suzuki M, Fujimura T, Fukuhara H, Enomoto Y, Nishimatsu H, Homma Y. Distant metastasis of renal cell carcinoma with a diameter of 3 cm or less-which is aggressive cancer? J Urol, 184, 64-68, 2010.
86. Kitamura T, Suzuki M, Nishimatsu H, Kurosaki T, Enomoto Y, Fukuhara H, Kume H, Takeuchi T, Miao L, Jiangang H, Xiaoqiang L. Final report on low-dose estramustine phosphate (EMP) monotherapy and very low-dose EMP therapy combined with LH-RH agonist for previously untreated advanced prostate cancer. Aktuelle Urol, 41, S34-40, 2010.
87. Hiraike H, Wada-Hiraike O, Nakagawa S, Koyama S, Miyamoto Y, Sone K, Tanikawa M, Tsuruga T, Nagasaka K, Matsumoto Y, Oda K, Shoji K, Fukuhara H, Saji S, Nakagawa K, Kato S, Yano T, Taketani Y. Identification of DBC1 as a transcriptional repressor for BRCA1. Br J Cancer, 102, 1061-1064, 2010.
88. Koyama S, Wada-Hiraike O, Nakagawa S, Tanikawa M, Hiraike H, Miyamoto Y, Sone K, Oda K, Fukuhara H, Nakagawa K, Kato S, Yano T, Taketani Y. Repression of estrogen receptor beta function by putative tumor suppressor DBC1. Biochem Biophys Res Commun, 392, 357-362, 2010.
89. Liu TC, Zhang T, Fukuhara H, Kuroda T, Todo T, Canron X, Bikfalvi A, Martuza RL, Kurtz A and Rabkin SD. Dominant-Negative FGF Receptor Expression Enhances Antitumoral Potency of Oncolytic HSV in Neural Tumors. Clin. Cancer Res., 12, 6791-6799, 2006.
90. Liu TC, Zhang T, Fukuhara H, Kuroda T, Todo T, Martuza RL, Rabkin SD and Kurtz A. HSV Armed with Platelet Factor 4, an Antiangiogenic Agent, Shows Enhanced Efficacy. Mol. Ther., 14, 789-797, 2006.
91. Fukuhara H, Matsumoto A, Kitamura T and Takeuchi T. Neutralization of interleukin-2 retarded the growth of mouse renal cancer. BJU Int., 97, 1314-1321, 2006.
92. Ino Y, Saeki Y, Fukuhara H and Todo T. Triple combination of oncolytic HSV-1 Vectors “armed” with interleukin 12, interleukin 18 or soluble B7-1 results in enhanced antitumor efficacy. Clin. Cancer Res., 12(2), 643-652, 2006.
93. Fukuhara H, Martuza RL, Rabkin SD, Ito Y and Todo T. Oncolytic Herpes Simplex Virus Vector G47∆ in Combination with Androgen Ablation for the Treatment of Human Prostate Adenocarcinoma. Clin. Cancer Res., 11(21), 7886-7890, 2005.
94. Fukuhara H, Ino Y, Kuroda T, Martuza RL and Todo T. Triple gene-deleted oncolytic herpes simplex virus vector double-armed with IL-18 and soluble B7-1 constructed by Bacterial Artificial Chromosome-mediated system. Cancer Res., 65(23), 10633-10668, 2005.
95. Sato F, Fukuhara H, and Basilion1 JP. Effects of Hormone Deprivation and 2-Methoxyestradiol Combination Therapy on Hormone Dependent Prostate Cancer In Vivo. Neoplasia, 7(9), 838-846, 2005.
96. Fukami T, Satoh H, Williams YN, Masuda M, Fukuhara H, Maruyama T, Yageta M, Kuramochi M, Takamoto S, Murakami Y. Isolation of the mouse Tsll1 and Tsll2 genes, orthologues of the human TSLC1-like genes 1 and 2 (TSLL1 and TSLL2). Gene. 323, 11-18, 2003.
97. Konno-Takahashi N, Takeuchi T, Shimizu T, Nishimatsu H, Fukuhara H, Kamijo T, Moriyama N, Tejima S and Kitamura T. Engineered IGF-1 expression induces glandular enlargement in the murine prostate. J. Endocrinol., 177, 389-398, 2003.
98. Fukuhara H, Masuda M, Yageta M, Fukami T, Kuramochi M, Maruyama T, Kitamura T and Murakami Y. Association of a lung tumor suppressor TSLC1 with MPP3, a human homologue of Drosophila tumor suppressor Dlg. Oncogene, 22, 6160-6165, 2003.
99. Fukami T, Fukuhara H, Kuramochi M, Maruyama T, Isogai K, Sakamoto M, Takamoto S, Murakami Y. Promoter methylation of the TSLC1 gene in advanced lung tumors and various cancer cell lines. Int. J. Cancer., 107, 53-59, 2003.
100. Masuda M, Yageta M, Fukuhara H, Kuramochi M, Maruyama T, Nomoto A, Murakami Y. The tumor suppressor protein TSLC1 is involved in cell-cell adhesion. J. Biol. Chem., 277, 31014-31019, 2002.
101. Yageta M, Kuramochi M, Masuda M, Fukami T, Fukuhara H, Maruyama T, Shibuya M, Murakami Y. Direct association of TSLC1 and DAL-1, two distinct tumor suppressor proteins in lung cancer. Cancer Res., 62, 5129-5133, 2002.
102. Fukami T, Satoh H, Fujita E, Maruyama T, Fukuhara H, Kuramochi M, Takamoto S, Momoi T, Murakami Y. Identification of the Tslc1 gene, a mouse orthologue of the human tumor suppressor TSLC1 gene. Gene, 295, 7-12, 2002.
103. Fukuhara H, Kuramochi M, Fukami T, Kasahara K, Nobukuni T, Maruyama T, Isogai K, Sekiya T, Shuin T, Kitamura T, Reeves RH and Murakami Y.  Promoter methylation of the TSLC1 and tumor suppression by its gene product in human prostate cancer. Jpn J. Cancer Res., 93, 605-609, 2002.
104. Pletcher MT, Nobukuni T, Fukuhara H, Kuramochi M, Maruyama T, Sekiya T, Sussan T, Isomura M, Murakami Y, Reeves RH. Identification of tumor suppressor candidate genes by physical and sequence mapping of the TSLC1 region of human chromosome 11q23. Gene, 273, 181-189, 2001.
105. Fukuhara H, Kuramochi M, Nobukuni T, Fukami T, Saino M, Maruyama T, Nomura S, Sekiya T, Murakami Y. Isolation of the TSLL1 and TSLL2 genes, members of the tumor suppressor TSLC1-gene family encoding transmembrane proteins. Oncogene, 20, 5401-5407, 2001.
106. Kuramochi M*, Fukuhara H*, Nobukuni T*, Kanbe T, Maruyama T, Ghosh HP, Pletcher M, Isomura M, Onizuka M, Kitamura T, Sekiya T, Reeves RH, Murakami Y. TSLC1 is a tumor suppressor gene in human non-small cell lung cancer. Nature Genetics, 27, 427-430, 2001. (*These authors contributed equally.)
107. Fukuhara H, Maruyama T, Nomura S, Oshimura M, Kitamura T, Sekiya T, Murakami Y. Functional Evidence for the Presence of Tumor Suppressor Gene on Chromosome 10p15 in Human Prostate Cancers. Oncogene, 20, 314-319, 2001.
108. Murakami Y, Uejima H, Fukuhara H, Maruyama T, Oshimura M, Sekiya T. Construction of human-rodent hybrid cells containing single transferable fragments of human chromosome 10p. J. Hum. Genet. 45, 370-373, 2000.
109. Takeuchi T, Nishimatsu H, Ueki T, Kajiwara T, Fukuhara H, Ishida T, Moriyama N, Kitamura T. Differentially expressed mRNAs in androgen-independent but not androgen-dependent Shionogi carcinoma. Urol. Res., 28, 82-85, 2000.

2 欧文総説
1. Taguchi S, Fukuhara H*, Todo T. Oncolytic virus therapy in Japan: progress in clinical trials and future perspectives.Jpn J Clin Oncol. 2018, in press.
2. Taguchi S, Fukuhara H*, Homma Y, Todo T. Current status of clinical trials assessing oncolytic virus therapy for urological cancers. Int J Urol. 24, 342-351, 2017.
3. Fukuhara H, Ino Y, Todo T. Oncolytic virus therapy: A new era of cancer treatment at dawn. Cancer Sci. 107, 1373-1379, 2016.
4. Hirata Y, Morino K, Suzuki T, Guo Q, Fukuhara H and Aihara K. System identification and parameter estimation in mathematical medicine: examples demonstrated for prostate cancer. Quantitative Biology 4, 13-19, 2016.
5. Fukuhara H and Todo T. New generation of oncolytic herpes virus. Current Cancer Therapy Reviews, 11, 163-177, 2015.
6. Fukuhara H, Homma Y and Todo T. Oncolytic virus therapy for prostate cancer. Int J Urol, 17, 20-30, 2010.
7. Fukuhara H and Todo T. Oncolytic Herpes Simplex Virus Type 1 and Host Immune Responses. Current Cancer Drug Targets, 7, 149-155, 2007.
8. Fukuhara, H. and Todo, T. New generation, conditionally replicating herpes simplex virus G47∆ as a potential backbone vector for expressing foreign proteins. Drug Future, 28, 43-49, 2003.
所属学会 日本泌尿器科学会(代議員)、日本癌学会(評議員)、日本癌治療学会(代議員)、日本遺伝子治療学会(JSGT)(評議員)、日本排尿機能学会(代議員)、東京医学会、日本老年泌尿器科学会、日本内視鏡外科学会、日本ミニマム創泌尿器内視鏡外科学会、日本泌尿器内視鏡学会(代議員)、米国泌尿器科学会(AUA)、国際禁制学会(ICS)、日本泌尿器腫瘍学会、日本臨床腎移植学会
泌尿器科分子・細胞研究会(評議員)、泌尿器腫瘍放射線(GUTR)研究会、日本間質性膀胱炎研究会
公的な委員会等の役員・委員歴 日本遺伝子細胞治療学会(JSGCT) 理事
厚生労働省医師国家試験 医師試験委員
東京地方裁判所 専門委員
International Journal of Urology Editorial Board
ひとことメッセージ がん治療用ウイルスを用いたウイルス療法の確立を目指しています。
患者さんに負担の少ない低浸襲性手術(ロボット支援手術、腹腔鏡下手術)を専門としています。
このページのトップへ

PAGE TOP